After some confusion over the status of its regulatory filing in the EU, Russia’s COVID-19 vaccine, Sputnik V, has finally begun a rolling review at the European Medicines Agency, based on results from laboratory studies and clinical trials in adults.
The head of the Russian Direct Investment Fund, which has financed Sputnik V’s development, said on 4 March that the...







